0000950170-24-029582.txt : 20240311
0000950170-24-029582.hdr.sgml : 20240311
20240311203311
ACCESSION NUMBER: 0000950170-24-029582
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240307
FILED AS OF DATE: 20240311
DATE AS OF CHANGE: 20240311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hineline Lawrence J.
CENTRAL INDEX KEY: 0001585697
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36274
FILM NUMBER: 24739928
MAIL ADDRESS:
STREET 1: C/O INTRA-CELLULAR THERAPIES, INC.
STREET 2: 3960 BROADWAY
CITY: NEW YORK
STATE: NY
ZIP: 10032
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc.
CENTRAL INDEX KEY: 0001567514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364742850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 212-923-3344
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
FORMER COMPANY:
FORMER CONFORMED NAME: Oneida Resources Corp.
DATE OF NAME CHANGE: 20130122
4
1
ownership.xml
4
X0508
4
2024-03-07
0001567514
Intra-Cellular Therapies, Inc.
ITCI
0001585697
Hineline Lawrence J.
C/O INTRA-CELLULAR THERAPIES, INC.
430 EAST 29TH STREET
NEW YORK
NY
10016
false
true
false
false
SVP of Finance, CFO
true
Common Stock
2024-03-07
4
S
false
6514
66.26
D
6618
D
Common Stock
2024-03-07
4
S
false
6618
66.93
D
0
D
Common Stock
2024-03-10
4
M
false
5582
A
5582
D
Common Stock
2024-03-11
4
S
false
4453
65.28
D
1129
D
Common Stock
2024-03-11
4
S
false
1100
66.54
D
29
D
Common Stock
2024-03-11
4
S
false
29
67.32
D
0
D
Common Stock
2024-03-10
4
M
false
4539
56.73
A
4539
D
Common Stock
2024-03-11
4
S
false
4475
66.47
D
64
D
Common Stock
2024-03-11
4
S
false
64
67.12
D
0
D
Restricted Stock Units
2024-03-10
4
M
false
5582
0
D
Common Stock
5582
5582
D
Stock Option (right to purchase)
56.73
2024-03-10
4
M
false
4539
0
D
2032-03-09
Common Stock
4539
4539
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.8115 to $66.8069, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.81 to $67.145, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Restricted stock units convert into common stock on a one-for-one basis.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.05 to $65.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.13 to $66.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.96 to $66.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.0012 to $67.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Each restricted stock unit represents a contingent right to receive one share of common stock.
On March 10, 2022, the reporting person was granted 16,746 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
On March 10, 2022, the reporting person was granted options to purchase 13,616 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
/s/ Lawrence J. Hineline
2024-03-11